Shots:
- The company has begun P-III (ECLIPSE) trial of ASP-1929 (photoimmunotherapy) + Keytruda for HNSCC, with first patient treated at a site across the US. Recruitment is underway in Japan, Taiwan & other regions
- This global study aims at assessing safety & efficacy of ASP-1929 + Keytruda vs Keytruda-based SoC as a 1L treatment of patients (n=~400) with locoregional recurrent HNSCC without distant metastases. The 1EP includes OS & 2EPs are CRR & ORR
- The P-III trial was based on interim results (as of Aug 2023) from HNSCC arm (n=19) of prior P-Ib/II study, showing a 24mos. survival rate of 52.4% with mOS not reached & a tolerable safety profile
Ref: Rakuten Medical | Image: Rakuten Medical
Related News:- Rakuten Medical Highlights the Preclinical Results of RM-0256 at JCA 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
